# A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

> **NCT05364931** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 54 (actual)

## Conditions studied

- Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

## Interventions

- **DRUG:** Cotadutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05364931
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-14
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364931, "A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05364931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*